<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="brief-report" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="iso-abbrev">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="pmc-domain-id">82</journal-id><journal-id journal-id-type="pmc-domain">aac</journal-id><journal-id journal-id-type="publisher-id">aac</journal-id><journal-title-group><journal-title>Antimicrobial Agents and Chemotherapy</journal-title></journal-title-group><issn pub-type="ppub">0066-4804</issn><issn pub-type="epub">1098-6596</issn><publisher><publisher-name>American Society for Microbiology (ASM)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12057349</article-id><article-id pub-id-type="pmcid-ver">PMC12057349.1</article-id><article-id pub-id-type="pmcaid">12057349</article-id><article-id pub-id-type="pmcaiid">12057349</article-id><article-id pub-id-type="pmid">40227040</article-id><article-id pub-id-type="doi">10.1128/aac.00908-24</article-id><article-id pub-id-type="publisher-id">aac00908-24</article-id><article-id pub-id-type="publisher-id">aac.00908-24</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject></subj-group><subj-group subj-group-type="biological-terms"><compound-subject><compound-subject-part content-type="code">antimicrobial-chemotherapy</compound-subject-part><compound-subject-part content-type="label">Antimicrobial Chemotherapy</compound-subject-part></compound-subject></subj-group></article-categories><title-group><article-title>Population pharmacokinetic analysis of tobramycin in serum and ELF using data from patients with pneumonia</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Van Wart</surname><given-names initials="SA">Scott A.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Trang</surname><given-names initials="M">Michael</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="pa1" ref-type="author-notes"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0452-682X</contrib-id><name name-style="western"><surname>Safir</surname><given-names initials="MC">M. Courtney</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Santulli</surname><given-names initials="AR">Andrew R.</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3172-0847</contrib-id><name name-style="western"><surname>Rubino</surname><given-names initials="CM">Christopher M.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4891-6467</contrib-id><name name-style="western"><surname>Bhavnani</surname><given-names initials="SM">Sujata M.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor1" ref-type="corresp"/><email>SBhavnani@icpd.com</email></contrib><aff id="aff1"><label>1</label><institution-wrap><institution>Institute for Clinical Pharmacodynamics Inc</institution><institution-id institution-id-type="Ringgold">537914</institution-id><institution-id institution-id-type="ROR">https://ror.org/02gck7e73</institution-id></institution-wrap>, <city>Schenectady</city>, <state>New York</state>, <country>USA</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution>Enhanced Pharmacodynamics, LLC</institution></institution-wrap>, <city>Buffalo</city>, <state>New York</state>, <country>USA</country></aff></contrib-group><contrib-group><contrib contrib-type="editor"><role>Editor</role><name name-style="western"><surname>Leggett</surname><given-names initials="JE">James E.</given-names></name><aff><institution-wrap><institution>Providence Portland Medical Center</institution></institution-wrap>, <city>Portland</city>, <state>Oregon</state>, <country>USA</country></aff></contrib></contrib-group><author-notes><corresp id="cor1">Address correspondence to Sujata M. Bhavnani, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:SBhavnani@icpd.com">SBhavnani@icpd.com</email></corresp><fn fn-type="present-address" id="pa1"><p>Present address: Janssen Research and Development LLC, a Johnson and Johnson company, La Jolla Shores, California, USA</p></fn><fn fn-type="COI-statement"><p>The authors declare no conflict of interest.</p></fn></author-notes><pub-date publication-format="electronic" date-type="collection"><month>5</month><year>2025</year></pub-date><pub-date date-type="pub" publication-format="electronic"><day>14</day><month>4</month><year>2025</year></pub-date><volume>69</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">488138</issue-id><elocation-id>e00908-24</elocation-id><history><date date-type="received"><day>19</day><month>6</month><year>2024</year></date><date date-type="accepted"><day>21</day><month>11</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>14</day><month>04</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>08</day><month>05</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-05-08 10:25:22.233"><day>08</day><month>05</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 Van Wart et al.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Van Wart et al.</copyright-holder><ali:free_to_read start_date="2025-04-14"/><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="aac.00908-24.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="aac.00908-24.pdf"/><abstract abstract-type="primary"><title>ABSTRACT</title><p>Population pharmacokinetic analyses were undertaken to characterize epithelial lining fluid (ELF) penetration for tobramycin in pneumonia patients. A two-compartment model with zero-order intravenous input and first-order elimination linked to an effect site ELF compartment was utilized to determine the steady-state ELF penetration ratio of 0.51 for tobramycin. These results are useful to account for effect site exposure when performing analyses to support recommendations for aminoglycoside dosing regimens and interpretive criteria for <italic toggle="yes">in vitro</italic> susceptibility testing.</p></abstract><kwd-group><title>KEYWORDS</title><kwd>tobramycin</kwd><kwd>epithelial lining fluid</kwd><kwd>population pharmacokinetic analysis</kwd></kwd-group><counts><count count="1" count-type="supplementary-material"/><count count-type="authors" count="6"/><fig-count count="1"/><table-count count="2"/><ref-count count="21"/><page-count count="5"/><word-count count="2612"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>May 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>INTRODUCTION</title><p>Drug exposure at the infection site is important when evaluating dose and/or interpretive criteria for <italic toggle="yes">in vitro</italic> susceptibility testing of antimicrobial agents against pathogens of interest. Bronchoscopy with bronchoalveolar lavage (BAL) is used to determine concentrations in the epithelial lining fluid (ELF) of the respiratory tract, which is a relevant effect site for extracellular respiratory pathogens causing acute bacterial pneumonia and infective exacerbation of chronic bronchitis (<xref rid="B1" ref-type="bibr">1</xref>). While aminoglycosides are known for poor lung penetration and varied lung tissue concentrations related to the anatomical site sampled (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>), a better understanding of the ELF penetration of aminoglycosides is useful to facilitate the population pharmacokinetic (PK) modeling and simulation that can be carried out to support the assessment of dosing regimens and susceptibility test interpretive criteria for these agents. Thus, the literature was searched for studies in which patients administered an aminoglycoside underwent serum PK sampling, and had BAL fluid samples collected at various times across the dosing interval. Priority was given to studies that provided individual dosing, PK, demographic, and renal function data.</p><p>Several studies were identified but ultimately not considered due to the collection of serum and/or BAL fluid PK samples at a single time point in all subjects rather than staggering the PK sample collection times (<xref rid="B4" ref-type="bibr">4</xref><xref rid="B5" ref-type="bibr">&#8211;</xref><xref rid="B7" ref-type="bibr">7</xref>). Such studies are limited in their utility as a result of system hysteresis, which is characterized by ELF concentration-time profiles that are delayed relative to serum concentration-time profiles. The implication of system hysteresis is that true penetration of a drug into the ELF is difficult to quantify unless sufficient PK data are available to inform ELF and serum concentration-time profiles (<xref rid="B1" ref-type="bibr">1</xref>).</p><p>Three studies that did fit the search criteria evaluated gentamicin, netilmicin, or tobramycin (<xref rid="B8" ref-type="bibr">8</xref><xref rid="B9" ref-type="bibr">&#8211;</xref><xref rid="B10" ref-type="bibr">10</xref>). Of these three studies which evaluated the ELF penetration for aminoglycosides in the patient population of interest (i.e., with pneumonia), the study conducted for tobramycin by Carcas et al. (<xref rid="B10" ref-type="bibr">10</xref>) was ultimately selected for further analysis as it provided individual demographics, renal function estimates, and most importantly, time-matched ELF and serum concentration-time data by patient across the 8-h dosing interval.</p><p>In the study by Carcas et al. (<xref rid="B10" ref-type="bibr">10</xref>), steady-state ELF and serum PK samples were collected from 16 adult patients with pneumonia. Tobramycin was assumed to be administered at 1 mg/kg as a 30-minute intravenous (IV) infusion every 8 h (q8h) to all patients. However, the authors stated dose adjustment was performed as necessary to obtain peak and trough concentrations of approximately 8 and &lt;2 mg/L, respectively. Bronchoscopy with BAL was performed at least 2 days after dose adjustment to allow for steady-state serum concentrations to be reached. A BAL fluid sample was collected once for each patient at either 0.5, 2.0, 4.0, or 8.0 h after the previous tobramycin dose (four patients per time point), and urea-corrected ELF concentrations were determined. Tobramycin concentrations in serum were measured for all patients at each of the four time points.</p><p>The population PK analysis was conducted using NONMEM software version 7.4 (ICON Development Solutions, Ellicott City, MD), implementing the first-order conditional estimation method with interaction (<xref rid="B11" ref-type="bibr">11</xref>). A two-compartment model with zero-order IV input and first-order elimination, with a linked effect site compartment for ELF, was used to simultaneously characterize the time course of tobramycin in serum and ELF upon repeated IV dosing. This structural PK model used serum drug concentrations to drive appearance in and subsequent removal of drug from the ELF without impacting the serum PK data fitting. Calculated creatinine clearance was included as a covariate on clearance using a power function. Parameter estimates for the final population PK model are shown in <xref rid="T1" ref-type="table">Table 1</xref>. The hysteresis for tobramycin concentrations in the ELF as noted in other studies (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>) was adequately captured, and the equilibrium half-life was calculated to be approximately 12 minutes based on the first-order elimination rate constant from the ELF compartment (<italic toggle="yes">k</italic><sub>30</sub>). A visual predictive check (<xref rid="B12" ref-type="bibr">12</xref>) demonstrated excellent agreement between the simulated and observed data following a steady-state dose (<xref rid="F1" ref-type="fig">Fig. 1</xref>), indicating that the model reasonably captured the central tendency and variability in the plasma and ELF concentration-time data and should provide reasonable predictions when performing stochastic simulations. A structural PK model diagram, goodness-of-fit plots, individual predicted overlays, and a NONMEM control stream containing the model differential equations as well as the actual analysis data set are all provided in the <xref rid="SuF1" ref-type="supplementary-material">Supplemental Material</xref>.</p><table-wrap position="float" id="T1" orientation="portrait"><label>TABLE 1</label><caption><p>Final population PK parameter estimates based on serum and ELF PK data from patients with pneumonia published by Carcas et al. (<xref rid="B10" ref-type="bibr">10</xref>)<xref rid="T1_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" valign="top" colspan="1" rowspan="1">Parameter</th><th align="left" valign="top" colspan="1" rowspan="1">Final estimate</th><th align="left" valign="top" colspan="1" rowspan="1">% RSE</th></tr></thead><tbody><tr><td align="left" valign="top" colspan="1" rowspan="1">CL (L/h) for a typical 90 mL/min/1.73 m<sup>2</sup> patient<break/>CL-CLcr exponent</td><td align="left" valign="top" colspan="1" rowspan="1">3.26<break/>0.685</td><td align="left" valign="top" colspan="1" rowspan="1">6.41<break/>31.0</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Vc (L)<xref rid="T1_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">10.4</td><td align="left" valign="top" colspan="1" rowspan="1">7.03</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">CLd (L/h)</td><td align="left" valign="top" colspan="1" rowspan="1">0.518</td><td align="left" valign="top" colspan="1" rowspan="1">25.8</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Vp (L)<sup><xref rid="T1_FN2" ref-type="table-fn"><italic toggle="yes">b</italic></xref></sup></td><td align="left" valign="top" colspan="1" rowspan="1">10.4</td><td align="left" valign="top" colspan="1" rowspan="1">7.03</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1"><italic toggle="yes">k</italic><sub>13</sub> (h<sup>&#8722;1</sup>)</td><td align="left" valign="top" colspan="1" rowspan="1">1.81</td><td align="left" valign="top" colspan="1" rowspan="1">23.1</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1"><italic toggle="yes">k</italic><sub>30</sub> (h<sup>&#8722;1</sup>)</td><td align="left" valign="top" colspan="1" rowspan="1">3.69</td><td align="left" valign="top" colspan="1" rowspan="1">38.9</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">
<italic toggle="yes">&#969;</italic>
<sup>2</sup>
<sub>CL</sub>
<sup>
<xref rid="T1_FN3" ref-type="table-fn">
<italic toggle="yes">c</italic>
</xref>
</sup>
</td><td align="left" valign="top" colspan="1" rowspan="1">0.0488 (22.4% CV)</td><td align="left" valign="top" colspan="1" rowspan="1">31.6</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">
<italic toggle="yes">&#969;</italic>
<sup>2</sup>
<sub>Vc</sub>
<sup>
<xref rid="T1_FN3" ref-type="table-fn">
<italic toggle="yes">c</italic>
</xref>
</sup>
</td><td align="left" valign="top" colspan="1" rowspan="1">0.0488 (22.4% CV)</td><td align="left" valign="top" colspan="1" rowspan="1">31.6</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">
<italic toggle="yes">&#969;</italic>
<sup>2</sup>
<sub><italic toggle="yes">k</italic>30</sub>
<sup>
<xref rid="T1_FN3" ref-type="table-fn">
<italic toggle="yes">c</italic>
</xref>
</sup>
</td><td align="left" valign="top" colspan="1" rowspan="1">0.0488 (22.4% CV)</td><td align="left" valign="top" colspan="1" rowspan="1">31.6</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1"><italic toggle="yes">&#963;</italic><sup>2</sup> CCV for serum data</td><td align="left" valign="top" colspan="1" rowspan="1">0.0299 (17.3% CV)</td><td align="left" valign="top" colspan="1" rowspan="1">36.3</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1"><italic toggle="yes">&#963;</italic><sup>2</sup> Additive for ELF data</td><td align="left" valign="top" colspan="1" rowspan="1">0.264 (0.514 SD)</td><td align="left" valign="top" colspan="1" rowspan="1">61.6</td></tr></tbody></table><table-wrap-foot><fn id="T1_FN1"><label>
<sup>
<italic toggle="yes">a</italic>
</sup>
</label><p>CCV, constant coefficient of variation; CL, clearance; CLcr, calculated creatinine clearance; CLd, distributional clearance; CV, coefficient of variation; ELF, epithelial lining fluid; <italic toggle="yes">k</italic><sub>13</sub>, first-order distribution rate constant from the central compartment to the ELF compartment; <italic toggle="yes">k</italic><sub>30</sub>, first-order elimination rate constant from the ELF compartment; <italic toggle="yes">&#969;</italic><sup>2</sup>, interindividual variability; <italic toggle="yes">&#963;</italic><sup>2</sup>, residual variability; q8h; every 8 h; RSE, relative standard error; SD, standard deviation; Vc, volume of distribution in the central compartment; Vp, volume of distribution in the peripheral compartment.</p></fn><fn id="T1_FN2"><label>
<sup>
<italic toggle="yes">b</italic>
</sup>
</label><p>Due to model parameter identifiability concerns, Vc and Vp were constrained to have the same value during model fitting. The resulting volume of distribution at a steady-state of 20.8 L (or 0.297 L/kg for a 70-kg patient) was within the range of values (0.28&#8211;0.45 L/kg) previously reported (<xref rid="B13" ref-type="bibr">13</xref><xref rid="B14" ref-type="bibr">&#8211;</xref><xref rid="B18" ref-type="bibr">18</xref>).</p></fn><fn id="T1_FN3"><label>
<sup>
<italic toggle="yes">c</italic>
</sup>
</label><p>For model reduction purposes, the magnitude of the interindividual variability for CL, Vc, and <italic toggle="yes">k</italic><sub>30</sub> was constrained to have the same estimated value during model fitting.</p></fn></table-wrap-foot></table-wrap><fig position="float" fig-type="figure" id="F1" orientation="portrait"><label>Fig 1</label><caption><p>Visual predictive check for the population PK model to the tobramycin steady-state total-drug serum (A) and ELF (B) concentration-time data from pneumonia patients administered 1 mg/kg of tobramycin IV infused over 30 minutes q8h published by Carcas et al. (<xref rid="B10" ref-type="bibr">10</xref>). The black dashed line is the median of observed data (black dots). The solid blue line and shaded area are the overall median and 80% bootstrap confidence interval of medians for 1,000 simulations. The dashed blue lines denote the 90% prediction interval of the simulations. Bin boundaries are indicated along the upper edge of the plot panel (black line segments). ELF, epithelial lining fluid; q8h, every 8 h.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="aac.00908-24.f001.jpg"><alt-text>Graphs show plasma and ELF tobramycin concentrations over time since last dose. Black features are observed values with dashed lines at medians. Blue simulation features show point and shaded interval estimates of medians and dashed prediction limits.</alt-text></graphic></fig><p>Using the final population PK model, a simulation of 1,000 patients with pneumonia receiving tobramycin as a 1 mg/kg IV infusion for 30 minutes q8h for 14 days was performed after bootstrapping from the population of model development patients. Total-drug area under the concentration-time curve from time 0 to 8 h (AUC<sub>0&#8211;8</sub>) was calculated via numerical integration and maximum drug concentration (<italic toggle="yes">C</italic><sub>max</sub>) by direct observation using intensive serum and ELF concentration-time data. The ELF:serum penetration ratio was computed by dividing the ELF AUC<sub>0&#8211;8</sub> by the serum AUC<sub>0&#8211;8</sub>. Free-drug serum AUC<sub>0&#8211;8</sub> was not evaluated since the protein binding for tobramycin was reported to be negligible (<xref rid="B19" ref-type="bibr">19</xref>). Summary statistics of tobramycin steady-state total-drug serum and ELF <italic toggle="yes">C</italic><sub>max</sub>, time to <italic toggle="yes">C</italic><sub>max</sub> (<italic toggle="yes">T</italic><sub>max</sub>), and AUC<sub>0&#8211;8</sub> values, as well as the ELF penetration ratio, are presented in <xref rid="T2" ref-type="table">Table 2</xref> . The mean &#177; standard deviation (SD) of the simulated <italic toggle="yes">T</italic><sub>max</sub> in ELF was 1.0 &#177; 0.1 h. The mean &#177; SD total-drug ELF penetration ratio for tobramycin was determined to be 0.51 &#177; 0.12. This mean AUC-based ELF penetration ratio of 0.51 was considered to be more informative than the time-matched concentration ratio reported to be 0.30 at 0.5 h, 0.42 at 2.0 h, 0.64 at 4.0 h, and 1.53 at 8.0 h by Carcas et al. (<xref rid="B10" ref-type="bibr">10</xref>).</p><table-wrap position="float" id="T2" orientation="portrait"><label>TABLE 2</label><caption><p>Summary statistics of tobramycin steady-state total-drug serum and ELF <italic toggle="yes">C</italic><sub>max</sub>, AUC<sub>0&#8211;8</sub>, and ELF AUC<sub>0&#8211;8</sub> penetration ratios simulated using data from 1,000 virtual pneumonia patients administered 1 mg/kg of tobramycin IV infused over 30 minutes q8h<xref rid="T2_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" valign="top" colspan="1" rowspan="1">Metric</th><th align="left" valign="top" colspan="1" rowspan="1">Mean</th><th align="left" valign="top" colspan="1" rowspan="1">SD</th><th align="left" valign="top" colspan="1" rowspan="1">Median</th><th align="left" valign="top" colspan="1" rowspan="1">Minimum&#173;, maximum</th></tr></thead><tbody><tr><td align="left" valign="top" colspan="1" rowspan="1">Serum <italic toggle="yes">C</italic><sub>max</sub> (mg/L)</td><td align="left" valign="top" colspan="1" rowspan="1">6.60</td><td align="left" valign="top" colspan="1" rowspan="1">0.76</td><td align="left" valign="top" colspan="1" rowspan="1">6.56</td><td align="left" valign="top" colspan="1" rowspan="1">4.78, 9.64</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">ELF <italic toggle="yes">C</italic><sub>max</sub> (mg/L)</td><td align="left" valign="top" colspan="1" rowspan="1">2.79</td><td align="left" valign="top" colspan="1" rowspan="1">0.65</td><td align="left" valign="top" colspan="1" rowspan="1">2.70</td><td align="left" valign="top" colspan="1" rowspan="1">1.31, 6.08</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">ELF <italic toggle="yes">T</italic><sub>max</sub> (h)</td><td align="left" valign="top" colspan="1" rowspan="1">1.0</td><td align="left" valign="top" colspan="1" rowspan="1">0.1</td><td align="left" valign="top" colspan="1" rowspan="1">1.0</td><td align="left" valign="top" colspan="1" rowspan="1">0.7, 1.4</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Serum AUC<sub>0&#8211;8</sub> (mg&#8729;h/L)</td><td align="left" valign="top" colspan="1" rowspan="1">20.5</td><td align="left" valign="top" colspan="1" rowspan="1">5.2</td><td align="left" valign="top" colspan="1" rowspan="1">20.0</td><td align="left" valign="top" colspan="1" rowspan="1">8.44, 45.1</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">ELF AUC<sub>0&#8211;8</sub> (mg&#8729;h/L)</td><td align="left" valign="top" colspan="1" rowspan="1">10.3</td><td align="left" valign="top" colspan="1" rowspan="1">3.5</td><td align="left" valign="top" colspan="1" rowspan="1">9.75</td><td align="left" valign="top" colspan="1" rowspan="1">3.92, 30.1</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Ratio of ELF AUC<sub>0&#8211;8</sub>:serum AUC<sub>0&#8211;8</sub></td><td align="left" valign="top" colspan="1" rowspan="1">0.51</td><td align="left" valign="top" colspan="1" rowspan="1">0.12</td><td align="left" valign="top" colspan="1" rowspan="1">0.49</td><td align="left" valign="top" colspan="1" rowspan="1">0.23, 1.02</td></tr></tbody></table><table-wrap-foot><fn id="T2_FN1"><label>
<sup>
<italic toggle="yes">a</italic>
</sup>
</label><p>AUC<sub>0&#8211;8</sub>, area under the concentration-time curve from time 0 to 8 h; <italic toggle="yes">C</italic><sub>max</sub>, maximum serum concentration; ELF, epithelial lining fluid; q8h, every 8 h; SD, standard deviation; <italic toggle="yes">T</italic><sub>max</sub>, time of maximum serum concentration.</p></fn></table-wrap-foot></table-wrap><p>Although published data based on non-comparative studies assessing aminoglycoside ELF penetration (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>) and other more recent analyses (<xref rid="B13" ref-type="bibr">13</xref>) have demonstrated that ELF penetration is highly variable (50%&#8211;100%), our analysis based on informative individual data collected for tobramycin suggested the ELF penetration for aminoglycosides might conservatively be closer to the lower end of that range. Future analyses of such data across aminoglycosides, including newer agents that undergo clinical development and require this information for selecting effective dosing regimens, will be useful to confirm this assumption. Such information regarding ELF penetration ratio is useful for older antimicrobial agents like the aminoglycosides, which have undergone reassessment of dosing regimens and interpretive criteria for <italic toggle="yes">in vitro</italic> susceptibility testing (<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B21" ref-type="bibr">21</xref>).</p></sec></body><back><sec sec-type="supplementary-material" id="s2-1"><title>SUPPLEMENTAL MATERIAL</title><p specific-use="print-only">The following material is available online at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.1128/aac.00908-24" ext-link-type="uri">https://doi.org/10.1128/aac.00908-24</ext-link>.</p><supplementary-material id="SuF1" position="float" content-type="local-data" orientation="portrait"><object-id pub-id-type="doi">10.1128/aac.00908-24.SuF1</object-id><label>Supplemental material</label><caption><title>aac.00908-24-s0001.pdf</title><p>Structural PK model diagram, goodness-of-fit plots, individual predicted overlays, and a NONMEM control stream containing the model differential equations as well as the actual analysis data set.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="aac.00908-24-s0001.pdf" position="float" orientation="portrait"/></supplementary-material><p specific-use="online-only">ASM does not own the copyrights to Supplemental Material that may be linked to, or accessed through, an article. The authors have granted ASM a non-exclusive, world-wide license to publish the Supplemental Material files. Please contact the corresponding author directly for reuse. </p></sec><ref-list><title>REFERENCES</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rodvold</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Hope</surname><given-names>WW</given-names></string-name>, <string-name name-style="western"><surname>Boyd</surname><given-names>SE</given-names></string-name></person-group>. <year>2017</year>. <article-title>Considerations for effect site pharmacokinetics to estimate drug exposure: concentrations of antibiotics in the lung</article-title>. <source>Curr Opin Pharmacol</source><volume>36</volume>:<fpage>114</fpage>&#8211;<lpage>123</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.coph.2017.09.019</pub-id><pub-id pub-id-type="pmid">29096171</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rodvold</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>George</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Yoo</surname><given-names>L</given-names></string-name></person-group>. <year>2011</year>. <article-title>Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents</article-title>. <source>Clin Pharmacokinet</source><volume>50</volume>:<fpage>637</fpage>&#8211;<lpage>664</lpage>. doi:<pub-id pub-id-type="doi">10.2165/11594090-000000000-00000</pub-id><pub-id pub-id-type="pmid">21895037</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Drwiega</surname><given-names>EN</given-names></string-name>, <string-name name-style="western"><surname>Rodvold</surname><given-names>KA</given-names></string-name></person-group>. <year>2022</year>. <article-title>Penetration of antibacterial agents into pulmonary epithelial lining fluid: an update</article-title>. <source>Clin Pharmacokinet</source><volume>61</volume>:<fpage>17</fpage>&#8211;<lpage>46</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s40262-021-01061-7</pub-id><pub-id pub-id-type="pmid">34651282</pub-id><pub-id pub-id-type="pmcid">PMC8516621</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Braude</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Hornstein</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Klein</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Vas</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Rebuck</surname><given-names>AS</given-names></string-name></person-group>. <year>1983</year>. <article-title>Pulmonary disposition of tobramycin</article-title>. <source>Am Rev Respir Dis</source><volume>127</volume>:<fpage>563</fpage>&#8211;<lpage>565</lpage>. doi:<pub-id pub-id-type="doi">10.1164/arrd.1983.127.5.563</pub-id><pub-id pub-id-type="pmid">6846938</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mazzei</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Novelli</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>De Lalla</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Mini</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Periti</surname><given-names>P</given-names></string-name></person-group>. <year>1995</year>. <article-title>Tissue penetration and pulmonary disposition of tobramycin</article-title>. <source>J Chemother</source><volume>7</volume>:<fpage>363</fpage>&#8211;<lpage>370</lpage>. doi:<pub-id pub-id-type="doi">10.1179/joc.1995.7.4.363</pub-id><pub-id pub-id-type="pmid">8568547</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Boselli</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Breilh</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Djabarouti</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Guillaume</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Rimmel&#233;</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Gordien</surname><given-names>J-B</given-names></string-name>, <string-name name-style="western"><surname>Xuereb</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Saux</surname><given-names>M-C</given-names></string-name>, <string-name name-style="western"><surname>Allaouchiche</surname><given-names>B</given-names></string-name></person-group>. <year>2007</year>. <article-title>Reliability of mini-bronchoalveolar lavage for the measurement of epithelial lining fluid concentrations of tobramycin in critically ill patients</article-title>. <source>Intensive Care Med</source><volume>33</volume>:<fpage>1519</fpage>&#8211;<lpage>1523</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00134-007-0688-x</pub-id><pub-id pub-id-type="pmid">17530217</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Najmeddin</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Shahrami</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Azadbakht</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Dianatkhah</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rouini</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Najafi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ahmadi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sharifnia</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Mojtahedzadeh</surname><given-names>M</given-names></string-name></person-group>. <year>2020</year>. <article-title>Evaluation of epithelial lining fluid concentration of amikacin in critically Ill patients with ventilator-associated pneumonia</article-title>. <source>J Intensive Care Med</source><volume>35</volume>:<fpage>400</fpage>&#8211;<lpage>404</lpage>. doi:<pub-id pub-id-type="doi">10.1177/0885066618754784</pub-id><pub-id pub-id-type="pmid">29471721</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Panidis</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Markantonis</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Boutzouka</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Karatzas</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Baltopoulos</surname><given-names>G</given-names></string-name></person-group>. <year>2005</year>. <article-title>Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia</article-title>. <source>Chest</source><volume>128</volume>:<fpage>545</fpage>&#8211;<lpage>552</lpage>. doi:<pub-id pub-id-type="doi">10.1378/chest.128.2.545</pub-id><pub-id pub-id-type="pmid">16100136</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Valcke</surname><given-names>YJ</given-names></string-name>, <string-name name-style="western"><surname>Vogelaers</surname><given-names>DP</given-names></string-name>, <string-name name-style="western"><surname>Colardyn</surname><given-names>FA</given-names></string-name>, <string-name name-style="western"><surname>Pauwels</surname><given-names>RA</given-names></string-name></person-group>. <year>1992</year>. <article-title>Penetration of netilmicin in the lower respiratory tract after once-daily dosing</article-title>. <source>Chest</source><volume>101</volume>:<fpage>1028</fpage>&#8211;<lpage>1032</lpage>. doi:<pub-id pub-id-type="doi">10.1378/chest.101.4.1028</pub-id><pub-id pub-id-type="pmid">1555417</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Carcas</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Garc&#237;a-Satu&#233;</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Zapater</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Fr&#237;as-Iniesta</surname><given-names>J</given-names></string-name></person-group>. <year>1999</year>. <article-title>Tobramycin penetration into epithelial lining fluid of patients with pneumonia</article-title>. <source>Clin Pharmacol Ther</source><volume>65</volume>:<fpage>245</fpage>&#8211;<lpage>250</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0009-9236(99)70103-7</pub-id><pub-id pub-id-type="pmid">10096256</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Bauer</surname><given-names>RJ</given-names></string-name></person-group>. <year>2017</year>. <article-title>NONMEM users guides</article-title>. <source>NONMEM 7. Version 7.4.1 ICON P.c</source>. <publisher-loc>Gaithersburg, MD</publisher-loc></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bergstrand</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hooker</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Wallin</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Karlsson</surname><given-names>MO</given-names></string-name></person-group>. <year>2011</year>. <article-title>Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models</article-title>. <source>AAPS J</source><volume>13</volume>:<fpage>143</fpage>&#8211;<lpage>151</lpage>. doi:<pub-id pub-id-type="doi">10.1208/s12248-011-9255-z</pub-id><pub-id pub-id-type="pmid">21302010</pub-id><pub-id pub-id-type="pmcid">PMC3085712</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shin</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Sayed</surname><given-names>ARM</given-names></string-name>, <string-name name-style="western"><surname>Werkman</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Jiao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kumaraswamy</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bulman</surname><given-names>ZP</given-names></string-name>, <string-name name-style="western"><surname>Luna</surname><given-names>BM</given-names></string-name>, <string-name name-style="western"><surname>Bulitta</surname><given-names>JB</given-names></string-name></person-group>. <year>2024</year>. <article-title>Improved characterization of aminoglycoside penetration into human lung epithelial lining fluid via population pharmacokinetics</article-title>. <source>Antimicrob Agents Chemother</source><volume>68</volume>:<elocation-id>e0139323</elocation-id>. doi:<pub-id pub-id-type="doi">10.1128/aac.01393-23</pub-id><pub-id pub-id-type="pmid">38169309</pub-id><pub-id pub-id-type="pmcid">PMC10848756</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Aarons</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Vozeh</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wenk</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Weiss</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Follath</surname><given-names>F</given-names></string-name></person-group>. <year>1989</year>. <article-title>Population pharmacokinetics of tobramycin</article-title>. <source>Br J Clin Pharmacol</source><volume>28</volume>:<fpage>305</fpage>&#8211;<lpage>314</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1365-2125.1989.tb05431.x</pub-id><pub-id pub-id-type="pmid">2789924</pub-id><pub-id pub-id-type="pmcid">PMC1379949</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Touw</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Vinks</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Neef</surname><given-names>C</given-names></string-name></person-group>. <year>1997</year>. <article-title>Pharmacokinetic modelling of intravenous tobramycin in adolescent and adult patients with cystic fibrosis using the nonparametric expectation maximization (NPEM) algorithm</article-title>. <source>Pharm World Sci</source><volume>19</volume>:<fpage>142</fpage>&#8211;<lpage>151</lpage>. doi:<pub-id pub-id-type="doi">10.1023/a:1008633526772</pub-id><pub-id pub-id-type="pmid">9259030</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xuan</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>JF</given-names></string-name>, <string-name name-style="western"><surname>Nicolau</surname><given-names>DP</given-names></string-name>, <string-name name-style="western"><surname>Nightingale</surname><given-names>CH</given-names></string-name></person-group>. <year>2000</year>. <article-title>Population pharmacokinetics of tobramycin in hospitalized patients receiving once-daily dosing regimen</article-title>. <source>Int J Antimicrob Agents</source><volume>15</volume>:<fpage>185</fpage>&#8211;<lpage>191</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s0924-8579(00)00172-2</pub-id><pub-id pub-id-type="pmid">10926440</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Beringer</surname><given-names>PM</given-names></string-name>, <string-name name-style="western"><surname>Vinks</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Jelliffe</surname><given-names>RW</given-names></string-name>, <string-name name-style="western"><surname>Shapiro</surname><given-names>BJ</given-names></string-name></person-group>. <year>2000</year>. <article-title>Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration</article-title>. <source>Antimicrob Agents Chemother</source><volume>44</volume>:<fpage>809</fpage>&#8211;<lpage>813</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.44.4.809-813.2000</pub-id><pub-id pub-id-type="pmid">10722474</pub-id><pub-id pub-id-type="pmcid">PMC89775</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Touw</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Knox</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Smyth</surname><given-names>A</given-names></string-name></person-group>. <year>2007</year>. <article-title>Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis</article-title>. <source>J Cyst Fibros</source><volume>6</volume>:<fpage>327</fpage>&#8211;<lpage>333</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jcf.2006.12.007</pub-id><pub-id pub-id-type="pmid">17276147</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="book"><article-title>Tobramycin [package insert]</article-title>. <year>2024</year>. <publisher-loc>Lake Forest, IL</publisher-loc><publisher-name>Hospira, Inc</publisher-name></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="software"><person-group person-group-type="author"><collab>The United States Committee on Antimicrobial Susceptibility Testing (USCAST)</collab></person-group>. <year>2019</year>. <article-title>Aminoglycoside in vitro susceptibility test interpretive criteria evaluations</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.uscast.org/documents" ext-link-type="uri">http://www.uscast.org/documents</ext-link>.</mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="confproc"><person-group person-group-type="author"><collab>The United States Committee on Antimicrobial Susceptibility Testing (USCAST)</collab></person-group>. <year>2023</year>. <article-title>Re-evaluation of aminoglycoside in vitro susceptibility test interpretive criteria</article-title>. <conf-name>USCAST 2023 Virtual Public Meeting. February 8, 2023</conf-name>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.uscast.org/presentations" ext-link-type="uri">https://www.uscast.org/presentations</ext-link>.</mixed-citation></ref></ref-list></back></article></pmc-articleset>